Richard Scott Struthers, President and CEO of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), filed a Form 4 on August 11, 2026, reporting four stock option exercises executed on August 7, 2026.

Key Highlights

  • Four option exercises: Struthers exercised options covering 3,969, 4,422, 6,542, and 4,995 shares of common stock on August 7, 2026.
  • Exercise prices varied: The four tranches carried exercise prices of $25.19, $22.61, $15.29, and $20.02 per share, respectively.
  • Direct holdings after transactions: Following the exercises, Struthers directly held 424,706 shares of common stock.
  • Substantial indirect holdings: The filing also disclosed indirect holdings across eight family trusts, a spousal account, and a charitable trust, totaling 978,205 additional shares.
  • Remaining options: After the exercises, Struthers retained directly held options to purchase 172,281, 195,578, 259,058, and 244,205 shares under the four respective option grants.
  • Transaction code M: All four transactions were coded "M," indicating exercises of derivative securities.

Struthers Reports Four Option Exercises at Crinetics Pharmaceuticals

According to the filing, Struthers exercises shares under four separate stock option grants, all on August 7, 2026. The first tranche involved 3,969 shares at an exercise price of $25.19, with the price of the derivative security listed as $0. The second tranche covered 4,422 shares at $22.61, followed by a third of 6,542 shares at $15.29, and a fourth of 4,995 shares at $20.02. In each case, the filing reports the price of the derivative security as $0.

The filing's explanation of responses details the vesting schedules for three of the four options. According to the filing, options in the second, third, and fourth tranches vested on an initial date and then at 1/48th of the shares monthly thereafter, "subject to the Reporting Person's continued employment with the Issuer on each such vesting date." Expiration dates for the four options are listed as March 8, 2029, February 24, 2030, February 26, 2031, and February 29, 2032, respectively.

In addition to 424,706 directly held shares following the reported transactions, the filing discloses indirect ownership through eight family trusts holding 136,805, 106,000, 110,000, 100,000, 111,100, 111,100, 111,100, and 111,100 shares, respectively, plus 1,000 shares held by a spouse and 80,000 shares held by a charitable trust. The form was signed by Tobin Schilke as attorney-in-fact and dated August 11, 2026.

What Was Disclosed

The filing reported four stock option exercises by Crinetics Pharmaceuticals' President and CEO on August 7, 2026, covering a total of 19,928 shares at varying exercise prices, with resulting direct beneficial ownership of 424,706 shares and substantial additional indirect holdings.